Bank of America’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Bank of America’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-378,016	Closed	-$40.6M	–	8110
2023 Q1	$40.6M	Buy	378,016 +183,559	+94%	+$21.1M	﹤0.01%	1517
2022 Q4	$21.4M	Buy	194,457 +121,448	+166%	+$7.88M	﹤0.01%	1967
2022 Q3	$4.31M	Buy	73,009 +58,394	+400%	+$2.67M	﹤0.01%	3480
2022 Q2	$413K	Buy	14,615 +4,851	+50%	+$141K	﹤0.01%	5572
2022 Q1	$368K	Sell	9,764 -8,647	-47%	-$342K	﹤0.01%	6038
2021 Q4	$728K	Buy	18,411 +12,704	+223%	+$398K	﹤0.01%	5562
2021 Q3	$136K	Buy	5,707 +1,566	+38%	+$37K	﹤0.01%	6546
2021 Q2	$102K	Buy	4,141 +2,913	+237%	+$65K	﹤0.01%	6518
2021 Q1	$22K	Buy	+1,228	New	+$25.4K	﹤0.01%	6867

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Bank of America's RXDX Position: Q2 2023 in Review

Bank of America sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 378,016 shares — an estimated $40.6M sold.

Bank of America first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $40.6M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Bank of America reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Bank of America sold 378,016 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $40.6M.
Bank of America first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Bank of America's Prometheus Biosciences, Inc. Common Stock position peaked at $40.6M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Bank of America's 13F filing for Q2 2023, filed 14 Aug 2023.